Mowry Anna
Known title: CFO and TreasurerCIK: 0001856938
Mowry Anna's purchase track record
How the stock did after each of Mowry Anna's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since November 24, 2021
Stock higher 6 months later
50%
3 months: 0%
Median 6-month return
-13.8%
3 months: -20.2%
Beat the S&P 500
50%
median -4.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/29/2025 | NAUT | $11K | -14.1% | +181.3% | +15.8% |
| 8/19/2022 | NAUT | $40K | -13.6% | +0.9% | -3.5% |
| 6/27/2022 | NAUT | $15K | -29.2% | -40.1% | -1.8% |
| 11/24/2021 | NAUT | $69K | -26.3% | -28.6% | -15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NAUT | ▲ Buy | Open Market | 15,000 | $11K | 5/29/2025 | View on chart |
| NAUT | ▲ Buy | Open Market | 17,500 | $40K | 8/19/2022 | View on chart |
| NAUT | ▲ Buy | Open Market | 5,500 | $15K | 6/27/2022 | View on chart |
| NAUT | ▲ Buy | Open Market | 15,000 | $69K | 11/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target
Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.